K. Kyaw

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Antimetastatic Activity of Apoptolidin A by Upregulation of N-Myc Downstream-Regulated Gene 1 Expression in Human Colorectal Cancer Cells

D. Oh, H. Park, E. Bae, 2023, Pharmaceuticals.

Antitumor Activity of Piceamycin by Upregulation of N-Myc Downstream-Regulated Gene 1 in Human Colorectal Cancer Cells.

D. Oh, Sang Kook Lee, H. Park, 2022, Journal of natural products.

Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer

Donghwa Kim, Sang Kook Lee, J. Lee, 2022, Pharmaceuticals.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.